COX-2-derived prostacyclin confers atheroprotection on female mice by Egan Karine M, Lawson John A, Fries Susanne, Koller Beverley, Rader Daniel J, Smyth Emer M, Fitzgerald Garret A in Science (New York, N.Y.) (2004).

[PMID: 15550624] PubMed


Female gender affords relative protection from cardiovascular disease until the menopause. We report that estrogen acts on estrogen receptor subtype alpha to up-regulate the production of atheroprotective prostacyclin, PGI2, by activation of cyclooxygenase 2 (COX-2). This mechanism restrained both oxidant stress and platelet activation that contribute to atherogenesis in female mice. Deletion of the PGI2 receptor removed the atheroprotective effect of estrogen in ovariectomized female mice. This suggests that chronic treatment of patients with selective inhibitors of COX-2 could undermine protection from cardiovascular disease in premenopausal females.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.